NASDAQ:MGRM Monogram Orthopaedics Q2 2025 Earnings Report $6.22 +0.11 (+1.80%) Closing price 10/6/2025 07:06 PM EasternExtended Trading$6.22 0.00 (0.00%) As of 10/6/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Monogram Orthopaedics EPS ResultsActual EPS-$0.16Consensus EPS -$0.11Beat/MissMissed by -$0.05One Year Ago EPSN/AMonogram Orthopaedics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMonogram Orthopaedics Announcement DetailsQuarterQ2 2025Date8/15/2025TimeBefore Market OpensConference Call DateFriday, August 15, 2025Conference Call Time7:00AM ETUpcoming EarningsMonogram Orthopaedics' Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Tuesday, November 18, 2025 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Monogram Orthopaedics Earnings HeadlinesCritical Review: Spectral AI (NASDAQ:MDAI) and Monogram Orthopaedics (NASDAQ:MGRM)October 7 at 3:01 AM | americanbankingnews.comMonogram Technologies Inc. (MGRM) Shareholder/Analyst Call Prepared Remarks TranscriptSeptember 30, 2025 | seekingalpha.comNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.October 7 at 2:00 AM | Paradigm Press (Ad)Monogram Orthopaedics Faces Merger Review DelaySeptember 5, 2025 | tipranks.comMonogram Orthopaedics Delays 10-Q FilingAugust 15, 2025 | tipranks.comZimmer Biomet Announces Second Quarter 2025 Financial ResultsAugust 7, 2025 | prnewswire.comSee More Monogram Orthopaedics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monogram Orthopaedics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monogram Orthopaedics and other key companies, straight to your email. Email Address About Monogram OrthopaedicsMonogram Orthopaedics (NASDAQ:MGRM), traded on Nasdaq under the ticker MGRM, is a commercial-stage medical device company focused on developing and delivering personalized knee replacement solutions. The company’s mission centers on improving patient outcomes in knee arthroplasty by leveraging advanced design and manufacturing methods to tailor implants and instrumentation to each individual’s unique anatomy. At the core of Monogram’s offering is the Monogram Knee System, which combines proprietary imaging software with additive manufacturing techniques to produce patient-specific implants and surgical instruments. Preoperative MRI or CT scans are used to create a three-dimensional model of the patient’s knee, allowing the system to optimize implant geometry, alignment guides, and cutting blocks. This customized approach aims to enhance implant fit, reduce surgical times, and potentially improve post-operative function and comfort. Founded in 2018 and headquartered in Menlo Park, California, Monogram Orthopaedics has secured FDA 510(k) clearance for its partial knee replacement system and completed its first commercial cases in leading U.S. orthopedic centers. The company continues to expand its commercial footprint across the United States, with plans to pursue additional regulatory approvals and market entry in select international regions.View Monogram Orthopaedics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
